本文轉載自原廠電子報: CAR-T Immunotherapy | www.antibodies-online.com
| According to data from the U.S. Patent and Trademark Office (USPTO), the number of CAR-T related patents filed showed a sharp increase during the last decade. |
|
As revolutionary immuno-oncology changes to cancer treatment, cell therapies have attracted widespread attention with their high clinical remission rate in hematological cancers. Since 2018, cell therapies have accounted for more remissions than cancer vaccines, with chimeric antigen receptor T (CAR-T) therapies leading the global cell therapy development race. With rapid development in the past ten years, CAR-T immunotherapy has become a hot area in which commercial organizations compete fiercely and universities ans industry collaborate intensively.¹
According to data from the U.S. Patent and Trademark Office (USPTO), the number of CAR-T related patents filed showed a sharp increase during the last decade. In this context, the USA and China are leading the way with the largest increase in patent documents, followed by the European countries. A look at the most common targets in CAR-T patent documents reveals an interesting and clearly structured picture. CD19 is by far the most worked target, followed by BCMA, CD20, Mesothelin, PD-1/PD-L1.
|
|
|
|
Selection of Top Products related to the most relevant Targets
|
|
|
|
¹ Lyu, L., Feng, Y., Chen, X., & Hu, Y. (2020). The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape. Nature Biotechnology, 38(12), 1387-1394.
|
|
